Godavari Drugs (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Godavari Drugs Limited |
|||
|
Price: ₹116.25 | ||
| 52 Week Low: ₹86.99 52 Week High: ₹155.00 |
|||
| Market Capital: 86.93 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Godavari Drugs Share Price Target For 2024
- 1.1.1: Godavari Drugs Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Godavari Drugs Share Price Target For 2025
- 1.2.1: Godavari Drugs Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Godavari Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Godavari Drugs Financial Performance
- 3.0.1: Is Godavari Drugs A Good Buy For Long Term?
To predict the Godavari Drugs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Godavari Drugs Share Price Target For 2024
The line chart displays the monthly closing prices of Godavari Drugs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Godavari Drugs shares in 2024, see the table below.
Godavari Drugs Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 122.5 (+5.37%) | Price Action: 05 Dec 2024 Low |
| 2024 Target 2 | 121.1 (+4.17%) | Price Action: 06 Dec 2024 Low |
| 2024 Target 1 | 119.9 (+3.13%) | Price Action: 18 Nov 2024 High |
| Current Price | 116.25 | Godavari Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 114.51 (-1.5%) | Technical Indicator: MA150 |
| Stop Loss 2 | 113.2 (-2.63%) | Price Action: 19 Dec 2024 Low |
| Stop Loss 3 | 112.0 (-3.66%) | Price Action: 06 Sep 2023 High |
Short-Term Technical Outlook
Current Technical Position: Godavari Drugs is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹119.07 serves as the nearest technical reference point.
Historical Returns: 3-month: -7.26% | 6-month: +14.68% | 1-year: +29.08%
Godavari Drugs Share Price Target For 2025
The line chart displays the monthly closing prices of Godavari Drugs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Godavari Drugs shares in 2025, see the table below.
Godavari Drugs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 165.07 (+41.99%) | Price Action: Chart |
| 2025 Target 2 | 161.99 (+39.34%) | Price Action: Chart |
| 2025 Target 1 | 160.39 (+37.96%) | Fibonacci Extension Level 64.90% |
| Current Price | 116.25 | Godavari Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 99.99 (-13.99%) | Price Action: 28 Jun 2024 Low |
| Stop Loss 2 | 98.99 (-14.85%) | Price Action: 30 Nov 2023 High |
| Stop Loss 3 | 98.0 (-15.7%) | Price Action: 18 Aug 2023 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Godavari Drugs is currently trading at 43.0% of its 52-week range (₹86.99 - ₹155).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +29.08% | 3-year: +85.55% | 5-year: +628.84%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Godavari Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹116.25 | ||
| 2024 | ₹134.53 | +15.72% | ₹136.55 |
| 2025 | ₹169.16 | +25.74% | ₹171.70 |
| 2026 | ₹204.93 | +21.14% | ₹208.00 |
| 2027 | ₹246.24 | +20.15% | ₹254.65 |
| 2028 | ₹296.96 | +20.59% | ₹301.41 |
| 2029 | ₹330.16 | +11.17% | ₹335.11 |
| 2030 | ₹359.73 | +8.95% | ₹366.48 |
| 2031 | ₹393.33 | +9.34% | ₹404.91 |
| 2032 | ₹437.47 | +11.22% | ₹454.99 |
| 2033 | ₹496.57 | +13.5% | ₹504.02 |
| 2034 | ₹525.79 | +5.88% | ₹533.68 |
| 2035 | ₹550.29 | +4.65% | ₹562.35 |
| 2036 | ₹581.73 | +5.71% | ₹605.25 |
| 2037 | ₹628.70 | +8.07% | ₹655.34 |
| 2038 | ₹696.18 | +10.73% | ₹706.62 |
| 2039 | ₹698.69 | +0.36% | ₹709.25 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Godavari Drugs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 86.93 Crore | Market valuation of Godavari Drugs's shares. |
| Revenue (TTM) | 156.71 Crore | Total revenue generated by Godavari Drugs over the past twelve months. |
| Net Income (TTM) | +5.54 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +6.83% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +22.9% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-16.64% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
1.48 | Company's total debt divided by total shareholder equity. |
| Total Debt | 57.77 Crore | Sum of Godavari Drugs's current & long-term financial obligations. |
| Total Cash | 11.88 Lakh | Total amount of liquid funds available to Godavari Drugs. |
Is Godavari Drugs A Good Buy For Long Term?
Godavari Drugs, a small-cap stock with a market capitalization of ₹86.93 crore, shows impressive growth over the past 3-5 years (227.14% and 387.23% respectively). However, Q1 2024-25 reveals a substantial debt of ₹57.77 crore against a meager cash balance of ₹11.88 lakh, and a significant -16.65% revenue drop quarter-over-quarter. While a 22.9% net profit margin is positive, the high debt-to-equity ratio raises significant concerns. Therefore, considering the current financial position, Godavari Drugs is not a good buy for long-term investment at this time. Further investigation into the reasons for the revenue decline is crucial before considering any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
